Murat Karabacak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Murat Karabacak has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Fatma Alibaz-Oner
Division of Rheumatology, Department of Internal Medicine, Marmara University, School of Medicine , Istanbul, Türkiye
4 shared publications - Haner Direskeneli
Division of Rheumatology, Department of Internal Medicine, Marmara University School of Medicine, İstanbul, Turkey
3 shared publications - Kerem Abacar
Leeds Institute of Rheumatic and Musculoskeletal Medicine University of Leeds and Chapel Allerton Hospital Leeds United Kingdom
3 shared publications - Seda Kutluğ Ağaçkıran
Department of Internal Medicine, Division of Rheumatology, Marmara University School of Medicine , Istanbul
3 shared publications - Tulin Ergun
Department of Dermatology, Marmara University School of Medicine, Istanbul, Türkiye
3 shared publications - Dilek Seçkin
Department of Dermatology Marmara University Faculty of Medicine İstanbul Turkey
2 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 56 (5) , 1420-1429
Turkish translation, cultural adaptation, and validation of the patient-reported Villalta scale for the diagnosis of postthrombotic syndrome in patients with vascular Behçet disease
Background/aim: Lower extremity deep vein thrombosis (DVT) constitutes 70% of all vascular findings related to Behçet disease (BD). Postthrombotic syndrome (PTS) is a serious complication of DVT that develops due to chronic venous insufficiency and decreases the patient’s quality of life. The physician-reported Villalta scale is a widely used and validated diagnostic tool for diagnosing and evaluating the severity of PTS. However, the necessity of physical examination by a physician burdens the clinician during routine practice. For that reason, a patient-reported Villalta scale was developed and validated. This study aimed to translate the patient-reported Villalta scale into Turkish and validate it. Materials and methods: All patients were evaluated using the physician-reported Villalta scale, Clinical-Etiological-Anatomical- Pathophysiological (CEAP) classification, Venous Clinical Severity Score (VCSS), Venous Disability Score (VDS), and patient-reported Villalta scale to diagnose PTS. The VEINES questionnaire and SF-36 were used to evaluate quality of life. Kappa and correlation analysis were performed for validation analysis. Results: One hundred patients with a history of DVT were enrolled in the study, 78 of whom were followed for BD. PTS developed in 52.5% of BD patients with DVT, which was significantly lower compared to non-BD patients (77.3%) (p = 0.038). PTS was detected in 58% (n = 58) of all patients. In kappa compliance analysis of the physician-reported and patient-reported Villalta scales, good agreement was observed (κ = 0.776, p < 0.001). Between the patient-reported and physician-reported Villalta scales, sensitivity was 98%, specificity 76%, positive predictive value 85%, and negative predictive value 97%. Conclusion: This study aimed to validate the Turkish version of the patient-reported Villalta scale to diagnose PTS. The Turkish version of the patient-reported Villalta scale can reliably and validly diagnose PTS. Its application in daily practice may offer useful guidance for clinicians.
- 15 October 2026
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 56 (5) , 1420-1429
Open AccessTurkish translation, cultural adaptation, and validation of the patient-reported Villalta scale for the diagnosis of postthrombotic syndrome in patients with vascular Behçet disease
Background/aim: Lower extremity deep vein thrombosis (DVT) constitutes 70% of all vascular findings related to Behçet disease (BD). Postthrombotic syndrome (PTS) is a serious complication of DVT that develops due to chronic venous insufficiency and decreases the patient’s quality of life. The physician-reported Villalta scale is a widely used and validated diagnostic tool for diagnosing and evaluating the severity of PTS. However, the necessity of physical examination by a physician burdens the clinician during routine practice. For that reason, a patient-reported Villalta scale was developed and validated. This study aimed to translate the patient-reported Villalta scale into Turkish and validate it. Materials and methods: All patients were evaluated using the physician-reported Villalta scale, Clinical-Etiological-Anatomical- Pathophysiological (CEAP) classification, Venous Clinical Severity Score (VCSS), Venous Disability Score (VDS), and patient-reported Villalta scale to diagnose PTS. The VEINES questionnaire and SF-36 were used to evaluate quality of life. Kappa and correlation analysis were performed for validation analysis. Results: One hundred patients with a history of DVT were enrolled in the study, 78 of whom were followed for BD. PTS developed in 52.5% of BD patients with DVT, which was significantly lower compared to non-BD patients (77.3%) (p = 0.038). PTS was detected in 58% (n = 58) of all patients. In kappa compliance analysis of the physician-reported and patient-reported Villalta scales, good agreement was observed (κ = 0.776, p < 0.001). Between the patient-reported and physician-reported Villalta scales, sensitivity was 98%, specificity 76%, positive predictive value 85%, and negative predictive value 97%. Conclusion: This study aimed to validate the Turkish version of the patient-reported Villalta scale to diagnose PTS. The Turkish version of the patient-reported Villalta scale can reliably and validly diagnose PTS. Its application in daily practice may offer useful guidance for clinicians.
- Open Access
- 16 January 2026
- Published by AVES YAYINCILIK A.Ş. in Archives of Rheumatology
- Vol. 41 (1) , 40-46
The Impact of Resistance Exercise Program on Muscle Strength, Functional Performance, and Quality of Life in Patients with Rheumatologic Disease Receiving High-Dose Glucocorticoids Treatment: A Randomized Trial
Background/Aims: This study aimed to evaluate the effectiveness of therapeutic exercises in improving muscle strength, functional status, and quality of life in patients receiving high-dose glucocorticoid therapy, which is known to cause muscle weakness and atrophy. Materials and Methods: This randomized, controlled, single-center study included 40 participants aged 18-65 years who received high-dose glucocorticoids due to chronic rheumatologic conditions, and the patients were divided into 2 groups: an exercise group and a control group. The exercise group performed lower-extremity resistance exercises for 3 months. The exercise program consisted of squats, seated leg extensions, seated leg curls, hip abductions, and seated calf raises performed 5 days per week. Functional assessments included the 6-minute walk test, the Five Times Sit To Stand Test, and the Timed Up and Go Test. Muscle strength was measured using a dynamometer, quality of life was assessed with the Short Form Health Survey questionnaire, and the cross-sectional area (CSA) of the rectus femoris muscle was evaluated via B-mode ultrasound. Patients were assessed at baseline and after 3 months of treatment. Results: Twenty patients were included in each group, with no significant differences in baseline characteristics. Compared with the control group, a significant increase was observed in knee extension strength (P = .00 for right and left knees) and quality of life in terms of physical function in the exercise group. However, no significant differences were found in the 6-minute walk test, the Five Times Sit To Stand Test, the Timed Up and Go Test, or the rectus femoris muscle CSA. Conclusion: In patients with rheumatologic diseases treated with highdose glucocorticoids, resistance exercise therapy can increase knee extension strength and quality of life in terms of physical function. Cite this article as: Karacaatlı M, Abacar K, Karabacak M, et al. The impact of resistance exercise program on muscle strength, functional performance, and quality of life in patients with rheumatologic disease receiving high-dose glucocorticoids treatment: A randomized trial. ArchRheumatol. 2026;41(1):40-46.
- 16 January 2026
- Published by AVES YAYINCILIK A.Ş. in Archives of Rheumatology
- Vol. 41 (1) , 40-46
Open AccessThe Impact of Resistance Exercise Program on Muscle Strength, Functional Performance, and Quality of Life in Patients with Rheumatologic Disease Receiving High-Dose Glucocorticoids Treatment: A Randomized Trial
Background/Aims: This study aimed to evaluate the effectiveness of therapeutic exercises in improving muscle strength, functional status, and quality of life in patients receiving high-dose glucocorticoid therapy, which is known to cause muscle weakness and atrophy. Materials and Methods: This randomized, controlled, single-center study included 40 participants aged 18-65 years who received high-dose glucocorticoids due to chronic rheumatologic conditions, and the patients were divided into 2 groups: an exercise group and a control group. The exercise group performed lower-extremity resistance exercises for 3 months. The exercise program consisted of squats, seated leg extensions, seated leg curls, hip abductions, and seated calf raises performed 5 days per week. Functional assessments included the 6-minute walk test, the Five Times Sit To Stand Test, and the Timed Up and Go Test. Muscle strength was measured using a dynamometer, quality of life was assessed with the Short Form Health Survey questionnaire, and the cross-sectional area (CSA) of the rectus femoris muscle was evaluated via B-mode ultrasound. Patients were assessed at baseline and after 3 months of treatment. Results: Twenty patients were included in each group, with no significant differences in baseline characteristics. Compared with the control group, a significant increase was observed in knee extension strength (P = .00 for right and left knees) and quality of life in terms of physical function in the exercise group. However, no significant differences were found in the 6-minute walk test, the Five Times Sit To Stand Test, the Timed Up and Go Test, or the rectus femoris muscle CSA. Conclusion: In patients with rheumatologic diseases treated with highdose glucocorticoids, resistance exercise therapy can increase knee extension strength and quality of life in terms of physical function. Cite this article as: Karacaatlı M, Abacar K, Karabacak M, et al. The impact of resistance exercise program on muscle strength, functional performance, and quality of life in patients with rheumatologic disease receiving high-dose glucocorticoids treatment: A randomized trial. ArchRheumatol. 2026;41(1):40-46.
- 18 February 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (2) , e70142
Case Series: Extracutaneous Findings of Eosinophilic Fasciitis Patients
Objective: Eosinophilic fasciitis (EF) is a connective tissue disorder characterized by cutaneous changes similar to scleroderma, usually associated with peripheral eosinophilia. This case series highlights clinical findings, particularly extracutaneous involvement, in EF patients to enhance clinician awareness of this rare condition.Methods: EF patients' skin and visceral organ involvement, musculoskeletal findings, laboratory tests (including acute phase reactants, autoantibodies, protein electrophoresis, etc.), magnetic resonance imaging (MRI), skin biopsy results, and treatments were evaluated.Results: The patient's age at presentation was 54 (range 23–68), and 50% were female. All patients presented with skin thickening in the distal upper extremities, except for the hands and feet. Notably, 50% of the patients showed involvement in the trunk, while 87.5% exhibited involvement in the distal lower extremities. A total of 87.5% of patients had increased acute‐phase reactants, and three‐quarters had peripheral eosinophilia. Some patients presented with extracutaneous manifestations such as nonspecific pulmonary nodules, neuropathy, or arthritis. MRI scans on all patients revealed notable thickening, contrast enhancement, and increased signal intensity within the fascia. Treatment involved the initiation of corticosteroids, with 87.5% of patients requiring the addition of an immunosuppressive agent due to an inadequate response. While no hematological malignancies were detected during the follow‐up period, solid cancer was detected in one patient.Conclusion: Patients diagnosed with EF should undergo a thorough evaluation for extracutaneous involvement, including joints, lungs, and muscles, as well as screening for occult malignancies. In instances where the condition does not respond to steroid therapy, it may be necessary to consider additional immunosuppressive treatments.
- 18 February 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (2) , e70142
Case Series: Extracutaneous Findings of Eosinophilic Fasciitis Patients
Objective: Eosinophilic fasciitis (EF) is a connective tissue disorder characterized by cutaneous changes similar to scleroderma, usually associated with peripheral eosinophilia. This case series highlights clinical findings, particularly extracutaneous involvement, in EF patients to enhance clinician awareness of this rare condition.Methods: EF patients' skin and visceral organ involvement, musculoskeletal findings, laboratory tests (including acute phase reactants, autoantibodies, protein electrophoresis, etc.), magnetic resonance imaging (MRI), skin biopsy results, and treatments were evaluated.Results: The patient's age at presentation was 54 (range 23–68), and 50% were female. All patients presented with skin thickening in the distal upper extremities, except for the hands and feet. Notably, 50% of the patients showed involvement in the trunk, while 87.5% exhibited involvement in the distal lower extremities. A total of 87.5% of patients had increased acute‐phase reactants, and three‐quarters had peripheral eosinophilia. Some patients presented with extracutaneous manifestations such as nonspecific pulmonary nodules, neuropathy, or arthritis. MRI scans on all patients revealed notable thickening, contrast enhancement, and increased signal intensity within the fascia. Treatment involved the initiation of corticosteroids, with 87.5% of patients requiring the addition of an immunosuppressive agent due to an inadequate response. While no hematological malignancies were detected during the follow‐up period, solid cancer was detected in one patient.Conclusion: Patients diagnosed with EF should undergo a thorough evaluation for extracutaneous involvement, including joints, lungs, and muscles, as well as screening for occult malignancies. In instances where the condition does not respond to steroid therapy, it may be necessary to consider additional immunosuppressive treatments.
- 13 November 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (5) , 2876-2881
Clinical course of paediatric-onset Behçet’s disease in young adulthood
Although Behçet's disease (BD) typically manifests in the second or third decade of life, initial symptoms may appear at a younger age. It may also take a longer time for the full disease phenotype to develop after the first symptom onset in pediatric patients. In this study we aimed to assess the clinical course of pediatric-onset BD in adulthood period. The files of 112 patients diagnosed with BD before the age of 18, selected from five tertiary clinics, were retrospectively examined. Patients with a follow-up of less than six months were excluded. The study comprised 93 patients with pediatric-onset BD, of whom 64.5% (n = 60) were male. The median age of diagnosis was 15 years (13–17). Major organ involvement was present in 49 (52.5%) patients. The most commonly affected organ was the eye (29%). Sixty-eight (73.1%) patients had follow-up data in adulthood. Fourty patients had only mucocutaneous manifestations in the pediatric period. During follow-up in adulthood, 15 (53.3% were male) had new major organ involvement with a mean of 10.1 (SD: 7.9) years after diagnosis. Twenty-eight patients (41.1%) experienced major organ involvement during the pediatric period. In adulthood follow-up, 12 (42.8%) developed new major organ involvement and/or relapse of the same organ. Eighteen (26.5%) of 68 pediatric-onset BD patients had new major organ involvement, and 9 (13.2%) had a relapse during adulthood follow-up. Our results showed that nearly one-third of pediatric BD patients have a new major organ involvement or a relapse in adulthood. Regular follow-up of pediatric BD patients in adulthood is essential to prevent long-term damage in this disease subset.
- 13 November 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (5) , 2876-2881
Clinical course of paediatric-onset Behçet’s disease in young adulthood
Although Behçet's disease (BD) typically manifests in the second or third decade of life, initial symptoms may appear at a younger age. It may also take a longer time for the full disease phenotype to develop after the first symptom onset in pediatric patients. In this study we aimed to assess the clinical course of pediatric-onset BD in adulthood period. The files of 112 patients diagnosed with BD before the age of 18, selected from five tertiary clinics, were retrospectively examined. Patients with a follow-up of less than six months were excluded. The study comprised 93 patients with pediatric-onset BD, of whom 64.5% (n = 60) were male. The median age of diagnosis was 15 years (13–17). Major organ involvement was present in 49 (52.5%) patients. The most commonly affected organ was the eye (29%). Sixty-eight (73.1%) patients had follow-up data in adulthood. Fourty patients had only mucocutaneous manifestations in the pediatric period. During follow-up in adulthood, 15 (53.3% were male) had new major organ involvement with a mean of 10.1 (SD: 7.9) years after diagnosis. Twenty-eight patients (41.1%) experienced major organ involvement during the pediatric period. In adulthood follow-up, 12 (42.8%) developed new major organ involvement and/or relapse of the same organ. Eighteen (26.5%) of 68 pediatric-onset BD patients had new major organ involvement, and 9 (13.2%) had a relapse during adulthood follow-up. Our results showed that nearly one-third of pediatric BD patients have a new major organ involvement or a relapse in adulthood. Regular follow-up of pediatric BD patients in adulthood is essential to prevent long-term damage in this disease subset.
- Open Access
- 14 March 2023
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 34 (3) , 310
RE: Risk of HBV Reactivation in HBsAg Negative and AntiHBc IgG Positive Patients Receiving Biologic Therapy
Cite this article as: Ergenç İ, Kani HT, Karabacak M, et al. RE: risk of HBV reactivation in HBsAg negative and anti-HBc IgG positive patients receiving biologic therapy. Turk J Gastroenterol. 2023;34(3):310.
- 14 March 2023
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 34 (3) , 310
Open AccessRE: Risk of HBV Reactivation in HBsAg Negative and AntiHBc IgG Positive Patients Receiving Biologic Therapy
Cite this article as: Ergenç İ, Kani HT, Karabacak M, et al. RE: risk of HBV reactivation in HBsAg negative and anti-HBc IgG positive patients receiving biologic therapy. Turk J Gastroenterol. 2023;34(3):310.
- Open Access
- 24 November 2022
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 34 (2) , 156-160
Biologic Therapy Carries a Very Low Risk of Reactivation in Hepatitis B Surface Antigen-Negative Phase of Hepatitis B
Background: The risk of hepatitis B reactivation in hepatitis B surface antigen-negative phase of hepatitis B virus-infected patients exposed to biologic agents is not clear. We aimed to investigate the reactivation rate in hepatitis B surface antigen-negative phase of hepatitis B virus-infected patients after biologic therapy. Methods: Patients followed at gastroenterology, rheumatology, and dermatology clinics with a diagnosis of immune-mediated inflammatory diseases were screened. Immune-mediated inflammatory diseases patients exposed to biologic agents with a negative hepatitis B surface antigen and positive hepatitis B core immunoglobulin G antibody were included in the study. Results: We screened 8266 immune-mediated inflammatory disease patients, and 2484 patients were identified as exposed to biologic agents. Two hundred twenty-one patients were included in the study. The mean age was 54.08 ± 11.69 years, and 115 (52.0%) patients were female. The median number of different biologic subtype use was 1 (range: 1-6). The mean biologic agent exposure time was 55 (range: 2-179) months. One hundred and fifty-two (68.8%) patients used a concomitant immunomodulatory agent, and 84 (38.0%) patients were exposed to corticosteroids during biologic use. No hepatitis B reactivation with a reverse seroconversion of hepatitis B surface antigen positivity was seen. Antiviral prophylaxis for hepatitis B was applied to 48 (21.7%) patients. Hepatitis B virus-DNA was screened in 56 (25.3%) patients prior to the biologic exposure. Two patients without antiviral prophylaxis had hepatitis B virus-DNA reactivation with a negative hepatitis B surface antigen during exposure to the biologic agent. Conclusion: We found 2 reactivations and no hepatitis B surface antigen seroconversion in our cohort. Antiviral prophylaxis for patients exposed to biologic agents may need to be discussed in more detail. Cite this article as: Ergenç İ, Kani HT, Karabacak M, et al. Biologic therapy carries a very low risk of reactivation in hepatitis B surface antigen-negative phase of hepatitis B. Turk J Gastroenterol. 2023;34(2):156-160.
- 24 November 2022
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 34 (2) , 156-160
Open AccessBiologic Therapy Carries a Very Low Risk of Reactivation in Hepatitis B Surface Antigen-Negative Phase of Hepatitis B
Background: The risk of hepatitis B reactivation in hepatitis B surface antigen-negative phase of hepatitis B virus-infected patients exposed to biologic agents is not clear. We aimed to investigate the reactivation rate in hepatitis B surface antigen-negative phase of hepatitis B virus-infected patients after biologic therapy. Methods: Patients followed at gastroenterology, rheumatology, and dermatology clinics with a diagnosis of immune-mediated inflammatory diseases were screened. Immune-mediated inflammatory diseases patients exposed to biologic agents with a negative hepatitis B surface antigen and positive hepatitis B core immunoglobulin G antibody were included in the study. Results: We screened 8266 immune-mediated inflammatory disease patients, and 2484 patients were identified as exposed to biologic agents. Two hundred twenty-one patients were included in the study. The mean age was 54.08 ± 11.69 years, and 115 (52.0%) patients were female. The median number of different biologic subtype use was 1 (range: 1-6). The mean biologic agent exposure time was 55 (range: 2-179) months. One hundred and fifty-two (68.8%) patients used a concomitant immunomodulatory agent, and 84 (38.0%) patients were exposed to corticosteroids during biologic use. No hepatitis B reactivation with a reverse seroconversion of hepatitis B surface antigen positivity was seen. Antiviral prophylaxis for hepatitis B was applied to 48 (21.7%) patients. Hepatitis B virus-DNA was screened in 56 (25.3%) patients prior to the biologic exposure. Two patients without antiviral prophylaxis had hepatitis B virus-DNA reactivation with a negative hepatitis B surface antigen during exposure to the biologic agent. Conclusion: We found 2 reactivations and no hepatitis B surface antigen seroconversion in our cohort. Antiviral prophylaxis for patients exposed to biologic agents may need to be discussed in more detail. Cite this article as: Ergenç İ, Kani HT, Karabacak M, et al. Biologic therapy carries a very low risk of reactivation in hepatitis B surface antigen-negative phase of hepatitis B. Turk J Gastroenterol. 2023;34(2):156-160.
- Open Access
- 30 August 2021
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 51 (4) , 1689-1694
Risk of tuberculosis is increased in Behçet’s disease compared to other rheumatological disorders after anti-TNFα treatments: a case series and review of the literature
Tumor necrosis factor-alfa (TNF-?) antagonists are extensively utilized in the treatment of inflammatory rheumatic diseases and also shown to be effective in Behcet?s disease (BD) patients with major organ involvement. In this study, we aimed to re-evaluate the incidence of tuberculosis (TB) infection after anti-TNF? treatments and to reveal the risk of TB in BD. Data of patients who received anti-TNF? treatment between 2005 and 2018 were assessed retrospectively. Demographic features, TNF-? antagonist type/treatment time, Tuberculosis skin test (TST) and QuantiFERON results, isoniazid prophylaxis status, and concomitant corticosteroid (CS) treatments were collected. A total of 1277 (male/female = 597/680; median age = 49 years) patients were treated with TNF-? antagonist for a median of 33 months (Q1:12, Q3:62). Thirteen (1%) patients developed TB during the follow-up period. Within 13 TB-positive patients, 7 of them had pulmonary, and 7 had extrapulmonary TB. Although, the median time of (month) TNF-? antagonist treatment was higher in TB-positive patients than negative ones, the difference was not statistically significant (48 and 33 months, respectively, p=0.47). Similarly, TB-positive patients were treated with CSs more than TB-negative patients (80% vs. 60%). Time from the initiation of TNF-? antagonist treatment to the diagnosis of TB had a median of 40 months (Q1-Q3: 22-56). There was a statistically significant increase of TB development in BD patients than non-BD patients after TNF-? antagonists (7.5% vs. 0.8%, respectively, p=0.007). When we combined our patients with the other series from Turkey, among 12928 patients who received TNF-? antagonists, TB was positive in 12 (3,9%) of 305 BD patients compared to 112 (0.9%) of 12623 non-BD patients (p<0.00001). Our results suggest a higher frequency of TB infections in BD patients with TNF-? antagonists. As biologic agents are increasingly used for major organ involvement in current practice for BD, screening mechanisms should be carefully implemented.
- 30 August 2021
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 51 (4) , 1689-1694
Open AccessRisk of tuberculosis is increased in Behçet’s disease compared to other rheumatological disorders after anti-TNFα treatments: a case series and review of the literature
Tumor necrosis factor-alfa (TNF-?) antagonists are extensively utilized in the treatment of inflammatory rheumatic diseases and also shown to be effective in Behcet?s disease (BD) patients with major organ involvement. In this study, we aimed to re-evaluate the incidence of tuberculosis (TB) infection after anti-TNF? treatments and to reveal the risk of TB in BD. Data of patients who received anti-TNF? treatment between 2005 and 2018 were assessed retrospectively. Demographic features, TNF-? antagonist type/treatment time, Tuberculosis skin test (TST) and QuantiFERON results, isoniazid prophylaxis status, and concomitant corticosteroid (CS) treatments were collected. A total of 1277 (male/female = 597/680; median age = 49 years) patients were treated with TNF-? antagonist for a median of 33 months (Q1:12, Q3:62). Thirteen (1%) patients developed TB during the follow-up period. Within 13 TB-positive patients, 7 of them had pulmonary, and 7 had extrapulmonary TB. Although, the median time of (month) TNF-? antagonist treatment was higher in TB-positive patients than negative ones, the difference was not statistically significant (48 and 33 months, respectively, p=0.47). Similarly, TB-positive patients were treated with CSs more than TB-negative patients (80% vs. 60%). Time from the initiation of TNF-? antagonist treatment to the diagnosis of TB had a median of 40 months (Q1-Q3: 22-56). There was a statistically significant increase of TB development in BD patients than non-BD patients after TNF-? antagonists (7.5% vs. 0.8%, respectively, p=0.007). When we combined our patients with the other series from Turkey, among 12928 patients who received TNF-? antagonists, TB was positive in 12 (3,9%) of 305 BD patients compared to 112 (0.9%) of 12623 non-BD patients (p<0.00001). Our results suggest a higher frequency of TB infections in BD patients with TNF-? antagonists. As biologic agents are increasingly used for major organ involvement in current practice for BD, screening mechanisms should be carefully implemented.